Development of novel therapeutics for chronic hepatitis B

Virologica Sinica

Volumn 25, Issue 4, 2010, Pages 294-300

  Xie, You Hua ^a   Hong, Ran ^b   Liu, Wei ^a   Liu, Jing ^a   Zhai, Jian Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Antiviral; Chronic infection; Hepatitis B virus (HBV); Treatment

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HETEROARYLDIHYDROPYRIMIDINE DERIVATIVE; INTERFERON; LAMIVUDINE; MIGLUSTAT; N NONYLDEOXYGALACTOJIRIMYCIN; N NONYLDEOXYNOJIRIMYCIN; PLACEBO; PROTEIN PRES1; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; ZINC FINGER PROTEIN;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; REVIEW; TREATMENT DURATION; VIRION; VIROGENESIS; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS MORPHOGENESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY;

HEPATITIS B VIRUS; MIRIDAE;

EID: 77956511552     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-010-3138-9     Document Type: Review

References (27)

1. Block T M, Lu X, Mehta A S, et al. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med, 4:610-614.
2. Chotiyaputta W, Lok A. 2009. hepatitis B virus variants. Nat Rev Gastroenterol Hepatol, 6:453-462.
3. Delaney W E 4th, Edwards R, Colledge D, et al. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 46:3057-3060.
4. Deng Q, Zhai J W, Michel M L, et al. 2007. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J Virol, 81:4244-4254.
5. Deres K, Schroder C H, Paessens A, et al. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science, 299:893-896.
6. Dienstag J L. 2008. Hepatitis B virus infection. N Engl J Med, 359:1486-1500.
7. Ganem D, Prince A M. 2004. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 350:1118-1129.
8. Glebe D, Urban S, Knoop E V, et al. 2005. Mapping of the hepatitis B virus attachment site by use of infection inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology, 129:234-245.
9. Gripon P, Cannie I, Urban S. 2005. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol, 79:1613-1622.
10. King R W, Ladner S K, Miller T J, et al. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-) β-L-2', 3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother, 42:3179-3186.
11. Lampertico P. Viganò M, Manenti E, et al. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology, 133:1445-1451.
12. Lazar C, Durantel D, Macovei A, et al. 2007. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res, 76:30-37.
13. Lucifora J, Durantel D, Testoni B, et al. 2010. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 51:63-72.
14. Mancini-Bourgine M, Fontaine H, Bréchot C, et al. 2006. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine, 24:4482-4489.
15. Mehta A, Carrouée S, Conyers B, et al. 2001. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology, 33:1488-1495.
16. Perrillo R. 2009. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 49: S103-111.
17. Petersen J, Dandri M, Mier W, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol, 26:335-341.
18. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev Immunol, 5:215-229.
19. Riordan S M, Skinner N, Kurtovic J, et al. 2006. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol, 13:972-974. (Pubitemid 44409640)
20. Seeger C, Mason W S. 2005. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000, 64:51-68.
21. Shepard C W, Simard E P, Finelli L, et al. 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, 28:112-125.
22. Thompson A J, Colledge D, Rodgers S, et al. 2009. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther, 14:797-808.
23. Vincent I E, Lucifora J, Durantel D, et al. 2009. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther, 14:131-135.
24. Weber O, Schlemmer K H, Hartmann E, et al. 2002. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res, 54:69-78.
25. Xu D Z, Zhao K, Guo L M, et al. 2008. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One, 3: e2565.
26. Yao X, Zheng B, Zhou J, et al. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine, 25:1771-1779.
27. Zimmerman K A, Fischer K P, Joyce M A, et al. 2008. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol, 82:8013-8021.